(0.05%) 5 310.99 points
(0.03%) 39 820 points
(0.05%) 16 803 points
(-1.64%) $78.49
(-1.38%) $2.71
(-0.64%) $2 422.90
(-1.84%) $31.83
(-0.48%) $1 058.60
(0.05%) $0.921
(-0.19%) $10.68
(-0.01%) $0.787
(-0.40%) $90.31
@ $5.26
发出时间: 15 Feb 2024 @ 03:48
回报率: -11.32%
上一信号: Feb 14 - 22:31
上一信号:
回报率: 2.24 %
Live Chart Being Loaded With Signals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...
Stats | |
---|---|
今日成交量 | 343 227 |
平均成交量 | 1.93M |
市值 | 424.72M |
EPS | $0 ( 2024-05-13 ) |
下一个收益日期 | ( $-0.250 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.19 |
ATR14 | $0.00900 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Carson William H. | Buy | 3 200 | Common Stock |
2024-04-08 | Carson William H. | Buy | 3 200 | Common Stock |
2024-02-16 | Love Douglas | Buy | 656 200 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 160 000 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 39 000 | Common Stock |
INSIDER POWER |
---|
80.76 |
Last 94 transactions |
Buy: 9 091 580 | Sell: 849 119 |
音量 相关性
Annexon, Inc. 相关性 - 货币/商品
Annexon, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2023 |
营收: | $0 |
毛利润: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2022 |
营收: | $0 |
毛利润: | $-3.31M (0.00 %) |
EPS: | $-2.53 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-7.68 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。